New cholesterol drugs show promise in Late-Stage trial
NCT ID NCT06717360
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 3 trial tested two new drugs, AG2304T and AG2304R, in 158 adults with primary hypercholesterolemia (high cholesterol). The study compared these drugs to an active control to see how well they lower LDL cholesterol and to check for side effects. Results could offer a new option for managing high cholesterol.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AG2304T and AG2304R (cholesterol-lowering drugs)
- What this could lead to
- If successful, this could provide a new treatment option for people with high cholesterol, helping to lower LDL cholesterol levels.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. The drugs may not prove more effective or safer than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
AhnGook
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill tame high cholesterol?
- Ancient herbal mix put to the test against high cholesterol
- Cookies that could fight cholesterol: pumpkin seeds and walnuts put to the test
- Could a daily pill help kids with inherited high cholesterol?
- Free meds and tailored education may cut heart risks in Low-Income seniors
- Can a smartphone app help lower bad cholesterol?